{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:32:05Z","timestamp":1768275125612,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1A6A1A10044154"],"award-info":[{"award-number":["2021R1A6A1A10044154"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022M3A9I2017587"],"award-info":[{"award-number":["2022M3A9I2017587"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ypmed.2023.107743","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:06:07Z","timestamp":1697774767000},"page":"107743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection"],"prefix":"10.1016","volume":"178","author":[{"given":"Wongyeong","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunha","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2023.107743_bb0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00019053-200927030-00006","article-title":"Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium","volume":"27","author":"Annemans","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ypmed.2023.107743_bb0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials","volume":"17","author":"Arbyn","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ypmed.2023.107743_bb0015","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.vaccine.2008.10.085","article-title":"Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence","volume":"27","author":"Bonanni","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.epidem.2022.100584","article-title":"Contact patterns and HPV-genotype interactions yield heterogeneous HPV-vaccine impacts depending on sexual behaviors: an individual-based model","volume":"39","author":"Bonneault","year":"2022","journal-title":"Epidemics"},{"key":"10.1016\/j.ypmed.2023.107743_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv282","article-title":"Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States","volume":"108","author":"Brisson","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2023.107743_bb0030","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0035","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.vaccine.2020.11.076","article-title":"Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence","volume":"39","author":"Brown","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0040","series-title":"Consumer Price Index (CPI)","author":"Bureau","year":"2023"},{"key":"10.1016\/j.ypmed.2023.107743_bb0045","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiq139","article-title":"Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease","volume":"203","author":"Chaturvedi","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05632-0","article-title":"Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study","volume":"21","author":"Cody","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(20)31558-0","article-title":"Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study","volume":"396","author":"de Figueiredo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ypmed.2023.107743_bb0060","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2023.107743_bb0065","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/infdis\/jiy067","article-title":"High effectiveness of the bivalent human papillomavirus (HPV) vaccine against incident and persistent HPV infections up to 6 years after vaccination in young Dutch women","volume":"217","author":"Donken","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0070","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ijc.28541","article-title":"Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine","volume":"134","author":"Drolet","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2023.107743_bb0075","series-title":"Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis","author":"Edejer","year":"2003"},{"key":"10.1016\/j.ypmed.2023.107743_bb0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0085","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","author":"Gold","year":"1998","journal-title":"Med. Care"},{"key":"10.1016\/j.ypmed.2023.107743_bb0090","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2023.107743_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1470-2045(22)00002-X","article-title":"Japan resumes active recommendations of HPV vaccine after 8\u00b75 years of suspension","volume":"23","author":"Haruyama","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ypmed.2023.107743_bb0105","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.ypmed.2023.107743_bb0110","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14760584.2021.1952869","article-title":"Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan","volume":"20","author":"Igarashi","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ypmed.2023.107743_bb0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0272989X07302128","article-title":"Abnormal outcomes following cervical cancer screening: event duration and health utility loss","volume":"27","author":"Insinga","year":"2007","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ypmed.2023.107743_bb0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ypmed.2023.107743_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-4801-x","article-title":"Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan","volume":"20","author":"Kawado","year":"2020","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0130","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.287.18.2382","article-title":"Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance","volume":"287","author":"Kim","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.ypmed.2023.107743_bb0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jiac.2019.09.005","article-title":"Stopping the HPV vaccine crisis in Japan: quantifying the benefits and risks of HPV vaccination in quality-adjusted life-years for appropriate decision-making","volume":"26","author":"Kitano","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.ypmed.2023.107743_bb0140","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/hv.28712","article-title":"Efficacy of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women","volume":"10","author":"Konno","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ypmed.2023.107743_bb0145","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1016\/j.vaccine.2021.08.085","article-title":"Access to HPV vaccination in Japan: increasing social trust to regain vaccine confidence","volume":"39","author":"Kunitoki","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0150","series-title":"Human Papillomavirus and Related Cancers, Fact Sheet, 2023 (Japan)","author":"Laia Bruni","year":"2023"},{"key":"10.1016\/j.ypmed.2023.107743_bb0155","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2014.07.099","article-title":"Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study","volume":"32","author":"Laprise","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/M19-1182","article-title":"Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States","volume":"172","author":"Laprise","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ypmed.2023.107743_bb0165","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ijc.25396","article-title":"Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication","volume":"128","author":"Li","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2023.107743_bb0170","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.vaccine.2022.05.025","article-title":"The cost-effectiveness of human papillomavirus vaccination in the Philippines","volume":"40","author":"Llave","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0175","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ypmed.2023.107743_bb0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clinthera.2014.11.002","article-title":"Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group","volume":"37","author":"Marcellusi","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ypmed.2023.107743_bb0185","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/vaccines8020221","article-title":"Prevalence, genotype distribution, and predictors against HPV infections targeted by 2-, 4-, 9-valent HPV vaccines among Japanese males","volume":"8","author":"Matsuzawa","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ypmed.2023.107743_bb0190","series-title":"2022 Overview of the Basic Survey on People's Livelihood","author":"Ministry of Health, L.a.W","year":"2023"},{"key":"10.1016\/j.ypmed.2023.107743_bb0195","series-title":"Human Papillomavirus Infection (HPV Vaccine)","article-title":"About the 9-valent human papillomavirus (HPV) vaccine (Silgard 9)","author":"Ministry of Health, L.a.W","year":"2023"},{"key":"10.1016\/j.ypmed.2023.107743_bb0200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vhri.2017.07.009","article-title":"Resource use and cost of treating human papillomavirus\u2013related lesions in Japanese women","volume":"15","author":"Mizukami","year":"2018","journal-title":"Value Health Reg. Issues"},{"key":"10.1016\/j.ypmed.2023.107743_bb0205","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","article-title":"Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis","volume":"151","author":"Myers","year":"2000","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ypmed.2023.107743_bb0210","series-title":"Proceedings of the 21st International Papillomavirus Conference","first-page":"2004","article-title":"Patient preferences for health states related to HPV infection: Visual analogue scales vs. time trade-off elicitation","author":"Myers","year":"2004"},{"key":"10.1016\/j.ypmed.2023.107743_bb0215","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jjco\/hyad017","article-title":"Age at first sexual intercourse among young women with invasive cervical cancer: implications for routine vaccination against human papillomavirus in Japan","volume":"53","author":"Nakazawa","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ypmed.2023.107743_bb0220","article-title":"Breaking down the stigma: reviving the HPV vaccination trust in Japan","volume":"146","author":"Namba","year":"2023","journal-title":"Qjm"},{"key":"10.1016\/j.ypmed.2023.107743_bb0225","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1620\/tjem.243.329","article-title":"Lower incidence of cervical intraepithelial neoplasia among young women with human papillomavirus vaccination in Miyagi, Japan","volume":"243","author":"Ozawa","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.ypmed.2023.107743_bb0230","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1016\/j.vaccine.2022.07.052","article-title":"Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis","volume":"40","author":"Palmer","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0235","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10198-018-0996-9","article-title":"Pricing of HPV vaccines in European tender-based settings","volume":"20","author":"Qendri","year":"2019","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.ypmed.2023.107743_bb0240","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jiac.2019.02.012","article-title":"Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women","volume":"25","author":"Sakamoto","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.ypmed.2023.107743_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect. Agent Cancer"},{"key":"10.1016\/j.ypmed.2023.107743_bb0250","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ."},{"key":"10.1016\/j.ypmed.2023.107743_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(20)30010-4","article-title":"Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study","volume":"5","author":"Simms","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ypmed.2023.107743_bb0260","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.ypmed.2023.107743_bb0265","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/cas.15320","article-title":"Trends in cervical cancer incidence and mortality of young and middle adults in Japan","volume":"113","author":"Tanaka","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ypmed.2023.107743_bb0270","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.31557\/APJCP.2019.20.5.1377","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in adolescent girls in Taiwan","volume":"20","author":"Tang","year":"2019","journal-title":"Asian Pacific J. Cancer Prevent."},{"key":"10.1016\/j.ypmed.2023.107743_bb0275","first-page":"1","article-title":"Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults","author":"Teng","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ypmed.2023.107743_bb0095","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ypmed.2023.107743_bb0280","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/jnci\/djz222","article-title":"Efficacy of the AS04-adjuvanted HPV16\/18 vaccine: pooled analysis of the Costa Rica vaccine and PATRICIA randomized controlled trials","volume":"112","author":"Tota","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ypmed.2023.107743_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1986333","article-title":"Changing trends in HPV vaccination in Japan","volume":"18","author":"Ujiie","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ypmed.2023.107743_bb0290","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1016\/j.vaccine.2008.07.098","article-title":"Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model","volume":"26","author":"Usher","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ypmed.2023.107743_bb0295","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ijc.32014","article-title":"Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012","volume":"144","author":"Utada","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ypmed.2023.107743_bb0300","series-title":"Cervical cancer","author":"WHO","year":"2022"},{"key":"10.1016\/j.ypmed.2023.107743_bb0305","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/vaccines9111263","article-title":"Cervical cancer protection in Japan: where are we?","volume":"9","author":"Yagi","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ypmed.2023.107743_bb0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/cas.12106","article-title":"Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years","volume":"104","author":"Yoshikawa","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ypmed.2023.107743_bb0315","series-title":"Cost-Effectiveness Analysis of Expanded National HPV Vaccination Program","author":"Yu","year":"2023"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743523003237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743523003237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:19:36Z","timestamp":1758795576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743523003237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"alternative-id":["S0091743523003237"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2023.107743","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2023.107743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107743"}}